Researchers have identified distinct longitudinal plasma proteomic trajectories associated with two different immunomodulatory therapies for chronic hepatitis B, suggesting that specific protein changes may correlate with favorable treatment responses. The study, published in Frontiers in Cellular and Infection Microbiology, examined how pegylated interferon-alpha (PEG-IFNα) and PD-1 blockade alter the circulating inflammatory proteome in patients whose viral replication is already suppressed by nucleos(t)ide analogues. By profiling plasma samples over a 24-week period, the team found that while both therapies induce immune remodeling, the breadth and timing of these changes differ significantly between the two treatment modalities.
The investigation focused on 25 patients with chronic hepatitis B who were receiving either PD-1 blockade or PEG-IFNα therapy. The cohort was divided into two groups: ten patients received PD-1 blockade, and fifteen patients received PEG-IFNα. All participants were nucleos(t)ide analogue-suppressed. Plasma samples were collected at three distinct time points: baseline, week 12, and week 24, providing a longitudinal view of how the proteome evolved in response to each therapy.
The researchers performed longitudinal plasma proteomic profiling using the Olink Target 96 Inflammation panel. Of the proteins measured, seventy-seven passed the quality-control criteria and were included in the final analysis. The study employed linear mixed-effects models to analyze longitudinal protein changes.
The primary results indicated that PEG-IFNα induced substantially broader longitudinal proteomic remodeling compared to PD-1 blockade. Most of the significant protein changes in the PEG-IFNα group occurred within the first 12 weeks of treatment. In contrast, the PD-1 blockade group showed a more limited range of proteomic shifts. Treatment-by-time analyses revealed distinct trajectories for the two therapies, highlighting differential changes in several key inflammatory markers, including IL-18R1, TNF, CX3CL1, CXCL9, and CXCL10.
The researchers also evaluated the association between these proteomic changes and clinical response, defined as a decline in hepatitis B surface antigen (HBsAg) of at least one log10 IU/mL by week 24. Using responder–non-responder comparisons and Spearman’s rank correlation, the team identified treatment-specific patterns linked to this favorable decline. In the PD-1 blockade cohort, IL-10 emerged as the leading exploratory signal associated with HBsAg decline. In the PEG-IFNα cohort, IL-12B, CDCP1, and FGF-21 were more prominent in the response-associated analyses.
However, the study emphasizes that these response-related associations did not remain significant after false discovery rate correction. Consequently, the authors classified these findings as exploratory rather than definitive biomarkers.
The findings support the potential value of longitudinal proteomics for mechanistic and biomarker studies of HBV functional-cure strategies. By demonstrating that favorable HBsAg decline is accompanied by treatment-specific rather than universal proteomic signatures, the research highlights the potential value of tracking dynamic immune changes over time.
Limitations of the study include the relatively small sample size, with only ten patients in the PD-1 blockade group and fifteen in the PEG-IFNα group.
Subject of Research: Longitudinal plasma proteomic profiling of PD-1 blockade and PEG-IFNα therapy in chronic hepatitis B
Article Title: Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B
Article References: Wang, H., Li, Y., Li, X., Zhang, X., Wang, Q., Liu, S., Yang, S., Zhang, X., Qiao, X., Dang, S., Wang, F.-S., & Fu, J. (2026). Distinct plasma proteomic trajectories during PD-1 blockade and PEG-IFNα therapy are associated with HBsAg response in chronic hepatitis B. Frontiers in Cellular and Infection Microbiology, 16, Article 1996565. https://doi.org/10.3389/fcimb.2026.1996565
Image Credits: AI Generated
DOI: 10.3389/fcimb.2026.1996565
Keywords: chronic hepatitis B, plasma proteomics, PD-1 blockade, PEG-IFNα, HBsAg decline, inflammatory proteins, immunomodulation, biomarkers, Olink panel, longitudinal study, Distinct, plasma
News Source: Kristina Jarvis. (November 10, 2026). Distinct proteomic patterns link hepatitis B treatments to HBsAg decline. Scienmag.



